相关实验视频
Updated: Feb 6, 2026

14:23
Design and Optimization Strategies of a High-Performance Vented Box
Published on: June 9, 2023
1.6K
在MOG抗体相关疾病中停止治疗的最佳策略
Wei Z Yeh1,2,3,4, Anna Francis1,2, Sarah Cooper5
1Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
Brain : a journal of neurology
|February 4, 2026
概括
停止免疫调节治疗髓寡基细胞糖蛋白抗体相关疾病 (MOGAD) 携带复发风险. 延长治疗时间,特别是对于复发的MOGAD,对于在停止治疗后减少复发风险至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 在停止治疗后,未知氨酸寡腺细胞糖蛋白抗体相关疾病 (MOGAD) 复发风险.
- 目前的证据表明,至少3个月的口服皮质类固醇可以减少单次发作后复发的风险.
- 在复发的MOGAD中,维持免疫调节治疗 (IT) 的最佳持续时间尚未确定.
研究的目的:
- 为了调查在MOGAD中维护免疫调节治疗中止后复发的结果.
- 为了确定与治疗停止后复发风险相关的因素.
- 在MOGAD中估计维护IT的最佳持续时间.
主要方法:
- 一项对来自牛津神经炎光学高度专业化服务的190名MOGAD患者的队列研究 (2010年1月 - 2025年5月).
- 纳入标准:MOGAD诊断,≥12个月的随访,开始和停止的维护IT.
- 考克斯回归分析,以调查治疗持续时间,病程和MOG IgG1状态与停药后的复发时间之间的关联.
主要成果:
- 停药后复发发生在236个治疗间隔中的39.0%.
- 停药后疾病复发过程 (HR 1.95) 和阳性MOG IgG1状态与复发风险增加有关.
- 长期治疗 (>3个月) 显著降低了复发风险.
结论:
- 在没有复发的患者考虑停止治疗之前,单相MOGAD的最佳治疗持续时间估计为10-18个月,复发MOGAD的20-30个月.
- 调查结果为考虑停止治疗的MOGAD患者提供援助管理决策.
- 证据支持稳定MOGAD患者考虑停止治疗的共享决策.
相关概念视频
Treatment Strategies for Psychological Disorders
786
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
786
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
959
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
959
Limits with Oscillating Discontinuities
472
An oscillating discontinuity is a type of discontinuity in which a function’s values fluctuate infinitely often as the input approaches a particular point. Unlike jump discontinuities, where the function suddenly shifts between two values, or infinite discontinuities, where the function diverges without bound, an oscillating discontinuity arises from rapid back-and-forth variation. Because the function never stabilizes toward a single value, no finite limit exists at that point.One of the...
472
Improper Integrals: Discontinuous Integrands
54
Evaluating Areas Under Curves with DiscontinuitiesA definite integral is considered improper when the integrand is discontinuous at one of the limits of integration. This occurs when the function is undefined or becomes infinite at an endpoint, making the corresponding region under the curve unbounded. Such behavior is commonly associated with vertical asymptotes at the boundary of the interval. To properly define and evaluate these integrals, a limiting process is used to determine whether a...
54
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
514
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
514

